Chiesi Group Completes $27/Share Acquisition of KalVista Pharmaceuticals
KALV has more than doubled off its 52-week low of $9.83.
Summary
Chiesi Group has completed its acquisition of KalVista Pharmaceuticals for $27.00 per share in cash. This finalizes the definitive agreement announced on April 29, 2026, which was followed by a tender offer and regulatory approvals. The completion means KalVista Pharmaceuticals will no longer be an independent public entity, and its shares are expected to be delisted from NASDAQ. Shareholders who tendered their shares will receive the agreed-upon cash consideration.
At the time of this announcement, KALV was trading at $26.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $9.83 to $27.00. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.